Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: $KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Karyopharm Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Karyopharm Therapeutics's position in the market.
Rhea-AI Summary
Karyopharm Therapeutics Inc. granted 10,250 restricted stock units to two new employees as part of its 2022 Inducement Stock Incentive Plan. Each RSU award will vest over three years, with specific conditions for accelerated vesting in case of a change in control event. The grants aim to attract and retain talent crucial for the company's growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.55%
Tags
-
Rhea-AI Summary
Karyopharm Therapeutics Inc. reports total revenue of $146 million for 2023, with U.S. XPOVIO® net product revenue at $112 million. The company expects top-line data readouts from pivotal Phase 3 trials in 2025. Full-year 2024 revenue guidance is set at $140-160 million, including U.S. XPOVIO net product revenue guidance of $100-120 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.78%
Tags
-
Rhea-AI Summary
Karyopharm Therapeutics Inc. (KPTI) will report its fourth quarter and full year 2023 financial results on February 29, 2024. The management team will host a conference call to discuss the results and company updates. Investors can access the call via dial-in or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.61%
Tags
Rhea-AI Summary
Karyopharm Therapeutics Inc. has granted 26,850 restricted stock units to seven newly-hired employees as part of its 2022 Inducement Stock Incentive Plan. The RSU awards will vest over three years, and each award is subject to the employee's continued service with the company. Additionally, the awards will be immediately exercisable in full in the event of a 'change in control event' and certain termination conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.56%
Tags
-
Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) expects top-line data readouts in 2H 2024 and 2025 from three pivotal Phase 3 studies evaluating Selinexor in Multiple Myeloma, Endometrial Cancer, and Myelofibrosis. Preliminary unaudited full year 2023 total revenue and U.S. XPOVIO (selinexor) net product revenue are expected to be approximately $146 million and $112 million, respectively. The company's cash runway is expected to extend into late 2025, supporting multiple potentially value-generating milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.92%
Tags
-
Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that its senior management team will participate in the 42nd Annual J.P. Morgan Healthcare Conference for a podium presentation and a question-and-answer breakout session. The live webcast of the presentation can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) grants 42,000 restricted stock units (RSUs) to a newly-hired employee. The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting is subject to the employee's continued service. Additionally, the RSU award will be immediately exercisable in full if a 'change in control event' occurs and the employee's employment is terminated for 'good reason' or terminated without 'cause' by Karyopharm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.55%
Tags
-
Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced long-term follow-up data from the Phase 1 study of Selinexor in combination with Ruxolitinib in treatment-naïve Myelofibrosis, suggesting disease modification and reinforcing the potential for this combination to become a novel, first-line treatment for JAKi-Naïve patients with MF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.53%
Tags
-
Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) granted 15,700 restricted stock units (RSUs) to three newly-hired employees as part of the Company's 2022 Inducement Stock Incentive Plan. The RSU awards will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting is subject to the employee's continued service, and the RSU award will be immediately exercisable in full in the event of a 'change in control event' and certain termination conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announces senior management participation in investor conferences in November, including Jefferies 2023 London Healthcare Conference and Piper Sandler 35th Annual Healthcare Conference. Live webcasts and slides available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.6%
Tags
Karyopharm Therapeutics Inc.
Nasdaq:KPTI
KPTI Rankings
KPTI Stock Data
113.27M
105.16M
5.99%
67.33%
19.94%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
NEWTON
About KPTI
karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com